Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 29, 2025Open Access

Stearoyl-CoA Desaturase-1 (SCD1) inhibition as a potential therapeutic strategy for targeting lung cancer stem cells

View Full Paper
Ask AI
Bookmark
Share

Authors

RHRobert Hsu

Discussion

Loading...

Member takes

Overview

This research investigates SCD1's role in lung cancer stem cells, suggesting potential therapeutic avenues by targeting ROS resistance.

Key Points

  • Inhibition of SCD1 led to increased death of lung cancer stem cells when treated with ROS inducers.
  • CSCs were found to express significantly higher levels of monounsaturated fatty acids and SCD1 than bulk A549 cells.
  • The study utilized quantitative real-time PCR and western blotting to assess SCD1 expression levels.
  • Targeting SCD1 may enhance the effectiveness of ROS-based treatments for lung cancer.

Cite This Study

Robert Hsu (2025) studied this question.

synapsesocial.com/papers/68da58c9c1728099cfd108e2https://doi.org/10.64336/001c.144857
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 2942: Inhibition of stearoyl-CoA desaturase 1 (SCD1) by SSI-4 as a therapeutic strategy in non-small cell lung cancer.2026
  2. 2FADS2 confers SCD1 inhibition resistance to cancer cells by modulating the ER stress response2024 · 5 citations
  3. 3Stearoyl-CoA desaturase 1 integrates tissue-specific oncogenic pathways into a pan-cancer ferroptosis resistance program2026
  4. 4Stearoyl CoA desaturase inhibition can effectively induce apoptosis in bladder cancer stem cells2024
  5. 5Stearoyl‐CoA Desaturase‐1 Drives Tumor Growth by Interacting With Histone Deacetylase‐2 and Deacetylating Nucleophosmin‐12026